ARS Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage
ARS Pharmaceuticals, Inc. (SPRY) reported Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage of 25.00% for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-10.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage · last filed 2025-11-10
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, award vesting rights, percentage for the quarter ending 2025-03-31 was 25.00%, a 0.00% change year-over-year.
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, award vesting rights, percentage for the quarter ending 2024-03-31 was 25.00%, a 0.00% change year-over-year.
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, award vesting rights, percentage for the quarter ending 2023-03-31 was 25.00%.
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, award vesting rights, percentage for fiscal 2024 was 25.00%, a 0.00% change from fiscal 2023.
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, award vesting rights, percentage for fiscal 2023 was 25.00%, a 0.00% change from fiscal 2022.
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, award vesting rights, percentage for fiscal 2022 was 25.00%, a 0.00% change from fiscal 2021.
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, award vesting rights, percentage for fiscal 2021 was 25.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage 12 month |
|---|---|---|---|---|
| 2025-09-30 | 25.00% 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | 25.00% 10-Q · filed 2025-08-13 | |||
| 2025-03-31 | 25.00% 10-Q · filed 2025-05-14 | |||
| 2024-12-31 | 25.00% 10-K · filed 2025-03-20 | |||
| 2024-09-30 | 25.00% 10-Q · filed 2024-11-13 | |||
| 2024-06-30 | 25.00% 10-Q · filed 2024-08-06 | |||
| 2024-03-31 | 25.00% 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | 25.00% 10-K · filed 2024-03-21 | |||
| 2023-09-30 | 25.00% 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | 25.00% 10-Q · filed 2023-08-10 | |||
| 2023-03-31 | 25.00% 10-Q · filed 2023-05-15 | |||
| 2022-12-31 | 25.00% 10-K · filed 2023-03-23 | |||
| 2021-12-31 | 25.00% 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |